Clinical Trials

Phase 3 trial of IV efgartigimod for the treatment of generalized MG. Completed.
Program: Efgartigimod

Phase 3 trial of IV efgartigimod for the treatment of primary ITP
Program: Efgartigimod

Phase 3 trial evaluating IV and SC efgartigimod for the treatment of primary ITP
Program: Efgartigimod

Confirmatory Phase 3 trial of IV efgartigimod for the treatment of primary ITP
Program: Efgartigimod

Phase 2 trial of SC Efgartigimod for the treatment of CIDP
Program: Efgartigimod

Phase 2 trial of IV efgartigimod for the treatment of PV. Active, not recruiting.
Program: Efgartigimod

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy
Program: Cusatuzumab

Cusatuzumab in Combination with Background Therapy for the Treatment of Participants with Acute Myeloid Leukemia
Program: Cusatuzumab

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants with Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome who are not Candidates for Intensive Treatment
Program: Cusatuzumab

A Study of Cusatuzumab in Combination with Azacitidine Compared with Azacitidine Alone in Patients with Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and who are not candidates for Hematopoietic Stem Cell Transplantation
Program: Cusatuzumab

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants with Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome who are not Candidates for Intensive Treatment
Program: Cusatuzumab

ARGX-117 clinical trial
Program: ARGX-117